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We aimed to develop a 68Ga-labeled single-chain variable fragment (scFv) targeting the human 
epidermal growth factor receptor 2 (HER2) to rapidly and noninvasively evaluate the status of 
HER2 expression 
Procedures 
Anti-HER2 scFv was labeled with 68Ga by using deferoxamine (Df) as a bifunctional chelate. 
Biodistribution of 68Ga-Df-anti-HER2 scFv was examined with tumor-bearing mice and positron 
emission tomography (PET) imaging was performed. The changes in HER2 expression after 
anti-HER2 therapy were monitored by PET imaging. 
Results 
68Ga-Df-anti-HER2 scFv was obtained with high radiochemical yield after only 5-min reaction at 
room temperature. The probe showed high accumulation in HER2-positive xenografts and the 
intratumoral distribution of radioactivity coincided with HER2-positive regions. Furthermore, 
68Ga-Df-anti-HER2 scFv helped visualize HER2-positive xenografts and monitor the changes in 
HER2 expression after anti-HER2 therapy. 
Conclusion 
68Ga-Df-anti-HER2 scFv could be a promising probe to evaluate HER2 status by in vivo PET 
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The human epidermal growth factor receptor 2 (HER2) is a member of ErbB family of 
receptor tyrosine kinases. Excessive HER2 signaling due to receptor overexpression is a hallmark of 
a wide variety of solid tumors, such as breast, gastric, and ovarian carcinomas [1-3]. Although 
overexpression of HER2 is related to aggressiveness and poor prognosis, trastuzumab, a 
recombinant monoclonal antibody against HER2 has positively influenced the prognosis of patients 
with HER2-positive breast cancer [4]. Thus, accurate assessment of HER2 status is essential to 
select the patients who may benefit from the anti-HER2 therapy. HER2 status is routinely 
determined by immunohistochemistry and/or fluorescence in situ hybridization, by using biopsy 
specimens in clinical practice [5]. However, the HER2 status in the biopsy specimens is not always 
representative of the whole tumor because of sampling bias and intratumoral heterogeneity [6]. 
Moreover, a relatively high discordance in HER2 expression in primary versus metastatic lesions 
has been reported [7], indicating a strong need for the reassessment of HER2 status associated with 
disease progression. Repetitive biopsy impairs the quality of life of the patients because of the 
invasiveness of the procedure. 
Radionuclide molecular imaging of HER2 can help avoid biopsy-associated issues, 
because this technique is noninvasive, quantitative, and directed to the whole body [8]. Clinical 
studies employing positron emission tomography (PET) by using trastuzumab radiolabeled with 
64Cu and 89Zr have been reported previously [9, 10]. Both probes visualized most of the known 
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lesions and some that had been undetected earlier. These results indicate that nuclear medicine 
imaging of HER2 is effective, as expected. However, the large molecular weight of trastuzumab 
(148 kDa) leads to some imaging problems due to the long biodistribution time, slow tumor 
penetration, and slow blood clearance of the tracers, which in turn reduces target to non-target 
contrast. Therefore, several types of radiolabeled trastuzumab fragments such as F(ab′) [11], 
diabody [12], and minibody [13] have been developed to fasten blood clearance and obtain 
successful HER2-positive tumor imaging. Nevertheless, there are no reports on the visualization of 
HER2-positive tumor in vivo by using radiolabeled single-chain Fv fragment (scFv). 
Since scFv shows rapid distribution and clearance, radionuclides with short half-lives are 
preferable for radiolabeling to reduce the radiation exposure of patients. Gallium-68 (half-life: 1.13 
h), a metallic positron emitter, is one such radionuclide. Moreover, 68Ga-labeled 
radiopharmaceuticals have high clinical availability, because they can be obtained from the 
68Ge/68Ga generator and their use does not require a cyclotron on site [14]. A variety of chelators 
have been developed to allow the formation of stable 68Ga complexes such as 
1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA). However, because 
68Ga-DOTA complexes need heat or long incubation to react, they are not suitable for rapid 
radiolabeling with biopharmaceuticals. On the other hand, p-isothiocyanatobenzyl derivative of 
deferoxamine (Df-p-SCN) is a convenient bifunctional chelate for labeling proteins at room 
temperature with 68Ga. This implies that scFv can maintain its immunoactivity during all reactions. 
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For this reason, we selected Df-p-SCN as a 68Ga-chelator. Although Df-conjugated antibody [15] 
and nanobody [16] have recently been reported, to the best of our knowledge, there has been no 
report on their application to scFv. 
In this study, we developed 67/68Ga-labeled Df-anti HER2 scFv to achieve faster blood 
clearance and better tumor-to-blood ratio at an early time point relative to that of trastuzumab. 
Furthermore, the changes in the expression levels of HER2 after treatment with 
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), which destabilizes HER2 




Preparation of Deferoxamine-conjugated anti-HER2 scFv (Df-anti-HER2 scFv) and 
non-radioactive Ga-Df-anti-HER2 scFv 
Anti-HER2 scFv (4D5-C10) with a COOH-terminal cysteine was a kind gift from CANON 
Inc. (Tokyo, Japan). The purity of anti-HER2 scFv (4D5-C10) was determined by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis and Coomassie staining. The 
p-isothiocyanatobenzyl derivative of deferoxamine (Df-p-SCN) was purchased from Macrocyclics, 
Inc. (Dallas, Tx). 
The scFv was incubated with Df-p-SCN (3 eq., 12 μL in dimethyl sulfoxide) at 37°C for 30 
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min, in a total volume of 0.8 mL of 50 mM NaHCO3. Nonconjugated chelate was removed by size 
exclusion chromatography using a PD-10 column (GE Healthcare Bio-Science AB, Uppsala, 
Sweden) with 0.25 M NaOAc (pH 5.5) as the eluent. The Df-anti-HER2 scFv was collected and 
concentrated by ultrafiltration (Amicon 10-kDa cut-off device; Millipore Corporation, Billerica, 
MA).  
Non-radioactive GaCl3 was added to 3 M NH4OAc to form Ga-acetate. Df-anti-HER2 scFv 
was incubated with Ga-acetate (10 eq., 7.3 μL in 3 M NH4OAc) at 37°C for 35 min, in a total 
volume of 0.5 mL of 0.25 M NaOAc (pH 5.5). Following purification using the PD-10 column, 
Ga-Df-anti-HER2 scFv was collected and concentrated by ultrafiltration. 
The molecular weight of anti-HER2 scFv, Df-anti-HER2 scFv, and Ga-Df-anti-HER2 scFv 
was determined by matrix-assisted laser desorption/ionization mass spectrometry (4800 Plus 
MALDI TOF/TOF™ Analyzer; AB SCIEX; Framingham, MA). 
 
Preparation of 67/68Ga-Df-anti-HER2 scFv 
67GaCl3 was kindly provided by FUJIFILM RI Pharma Co., Ltd. (Tokyo, Japan). 68Ge/68Ga 
generator was purchased from Eckert & Ziegler Isotope Products GmbH (Berlin, Germany).  
67GaCl3 was mixed with 3 M NH4OAc and incubated for at least 5 min to facilitate 
67Ga-acetate chelation. 68Ga was eluted from the generator and was concentrated using an anion 
exchange column (Chromafix, Macherey-Nagel GmbH & Co., Düren, Germany) [16]. The eluent 
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from the anion exchange column was mixed with 3 M NH4OAc to facilitate 68Ga-acetate chelation. 
67Ga-acetate (50 μL) or 68Ga-acetate (500 μL) were mixed with Df-anti-HER2 scFv in 0.25 M 
NaOAc (pH5.5) at room temperature for 5 min. Following purification by using the PD-10 column, 
67/68Ga-Df-anti-HER2 scFv was collected and used for further experiments. The radiochemical 
purity of the probes was determined by size-exclusion analysis using the PD-10 column. 
Size-exclusion high-performance liquid chromatography (SE-HPLC) was also performed (TSKgel 
SuperSW3000 [4.6 × 300 mm]; TOSOH Corporation, Tokyo, Japan; 100 mM phosphate buffer [pH 
6.6] containing 0.1 M Na2SO4, 0.3 mL/min; wave length, 280 nm). 
 
In vitro stability 
As described previously [17] with a slight modification, stability of 67Ga-Df-anti-HER2 
scFv was tested in 25 mM NaHCO3 solution containing 5 mg/mL apo-transferrin. After incubation 
for 1, 2, 3, and 24 h at 37°C, 50 μL of the sample was collected for analysis by SE-HPLC. The 
eluent was collected every minute for 20 min and radioactivity was measured with an automatic 
well-type γ-counter (AccuFLEX γ7001B; Hitachi Aloka Medical, Ltd.; Tokyo, Japan). The retention 
time for apo-transferrin (80 kDa), chicken ovalbumin (44 kDa), anti-HER2 scFv (27 kDa), and 
horse myoglobin (17 kDa) was 12.1, 12.6, 13.3, and 14.0 min, respectively. 
The stability of the probe in mouse plasma was also determined. Animal studies were 
conducted in accordance with our institutional guidelines, and the experimental procedures were 
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approved by the Kyoto University Animal Care Committee. Female BALB/c mice (5 weeks; 17–18 
g) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Blood was withdrawn from the hearts 
of euthanized mice (n = 3) using heparinized syringes, and plasma was obtained by centrifugation at 
1,000 × g for 5 min at 4°C. 67Ga-Df-anti-HER2 scFv (20 μL) was incubated in mouse plasma 
(100 μL) for 1 hr at 37°C, and then the sample was analyzed by SE-HPLC. 
To determine the distribution ratio of 67Ga-Df-anti-HER2 scFv in plasma and blood cells, 
the probe (20 μL) was incubated with mouse blood (200 μL) for 1 hr at 37°C. After incubation, the 
blood was centrifuged at 1,000 × g for 5 min at 4°C to separate plasma from blood cells. The 
radioactivity in each fraction was measured by the γ-counter. 
 
Cells and cell culture 
NCI-N87 human gastric cancer cells (N87) were obtained from American Type Culture 
Collection (Manassas, VA), and Suit-2 human pancreatic cancer cells were obtained from Human 
Science Research Resources Bank (Osaka, Japan). Both the cells were maintained in RPMI1640 
medium supplemented with 10% fetal bovine serum, 0.6 mg/mL L-glutamine, 1.8 mg/mL NaHCO3, 
100 U/mL penicillin, and 100 mg/mL streptomycin. 
 
Cell binding study 
N87 cells were plated in a 24-well plate at 1 × 105 cells per well. After 18-h incubation, the 
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culture medium was replaced by a medium containing 0.1–50 nM of 67Ga-Df-anti-HER2 scFv and 
incubated for 2 h at 4°C. After the incubation, the medium was removed, and the cells were washed 
with PBS twice and lysed with 0.2 N NaOH. The radioactivity of each well was measured by 
γ-counter and was normalized using the protein concentration in each well, which was determined 
by using BCA protein assay kit (Pierce, Rockford, IL). The equilibrium dissociation constant (KD) 




Female BALB/c nude mice (5 weeks; 18–22 g) were purchased from Japan SLC, Inc. N87 
and Suit-2 cells (5 × 106 cells each in 50% Geltrex Matrix [Life Technologies Corporation, Carlsbad, 
CA] in PBS) were subcutaneously transplanted into the right and left shoulders of the mice, 
respectively [18]. The mice were subjected to a tracer study at 4–6 weeks after the implantation. 
Before use, the tumor size was measured using a caliper, and the volume was calculated using the 
following equation: tumor volume = length × (width)2/2 [19]. The average volume of N87 and 
Suit-2 xenografts was 150–250 mm3 and 200–400 mm3, respectively.   
 
Biodistribution study 
67Ga-Df-anti-HER2 scFv (30–50 kBq/0.81–1.35 μg, 100 μL in NaOAc buffer) was injected 
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via the tail vein into the tumor-bearing mice (n = 4–5); the mice were dissected at 1, 2, and 3 h after 
the injection. Whole organs were immediately obtained and weighed, and their radioactivity was 
measured. The results are expressed in terms of the percent injected dose per gram of the tissue 
(%ID/g). 
 
Autoradiography and Immunohistochemistry 
Tumor-bearing mice (n = 2) received intraveneous injection of 67Ga-Df-anti-HER2 scFv 
(3.7 MBq). The mice were sacrificed at 2 h after the injection, and the tumors were removed and 
frozen in hexane (−80°C). The frozen tumor samples were cut into 20-µm–thick sections and 
adjacent 10-µm–thick sections. After 2-day exposure, autoradiograms were obtained, according to a 
previously described method [20, 21]. The adjacent 10-µm sections were subjected to 
immunohistochemical analyses for HER2 by using HercepTest (Dako, Denmark). Immunostaining 
was performed as per the manufacturer’s protocol. 
 
PET imaging 
Tumor-bearing mice (n = 2) were intravenously injected with 68Ga-Df-anti-HER2 scFv (9–
24 MBq/52–65 μg, 100 μL in NaOAc buffer). At 1, 2, and 3 h after injection, the mice were imaged 
for 20 min by using eXplore VISTA (GE Healthcare Bio-Science). The acquisition and 
reconstruction of images were performed according to a previously described method [22]. After 
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PET imaging, the mice were euthanized at approximately 3.25 h post injection. Tumors were 
immediately obtained and weighed, and their radioactivity was measured. 
 
Treatment protocol and in vivo monitoring of HER2 expression 
The mice (n = 9) were used for therapeutic study when their tumor volume reached 
approximately 100–300 mm3. Animals were divided in 3 groups (3 mice in each group). In one of 
the groups (vehicle-treated group), each animal received saline containing 10% DMSO and 10% 
ethanol, intravenously, once in a day for 3 consecutive days. The tumor size was monitored from 
Day 0, when the animals received the 1st dose of treatment to Day 14. In the other groups, a dose of 
50 mg/kg of 17-DMAG dissolved in saline containing 10% DMSO and 10% ethanol was 
administered via tail vein injection for 3 consecutive days (a total of 150 mg/kg of 17-DMAG). The 
tumor size was monitored from Day 0 to Day3 in 1 group and from Day 0 to Day14 in the other 
group. Tumor growth was monitored by caliper measurement, and tumor volume was calculated. 
After the final measurement of tumor size in the 17-DMAG-treated groups, 2 mice from 
each group were subjected to PET/X-ray computed tomography (CT) imaging. The mice were 
intravenously injected with 68Ga-Df-anti-HER2 scFv, and 2 h later, they were imaged for 20 min by 
using the FX3300 preclinical imaging system (Gamma Medica, Inc., Northridge, CA) under 2.5% 
isoflurane anesthesia. Coincident data were collected for 511 keV gamma rays with an energy 
window of 250–700 keV. PET images were reconstructed by using a 2-dimensional ordered-subset 
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expectation maximization algorithm (iterations, 20; subsets, 4), and regions of interest (ROIs) were 
drawn on the tumors. CT scannings were performed according to a previously described method 
[23]. After PET/CT imaging, each tumor was removed and frozen for further analysis by using 
western blotting. Before frozen, the radioactivity and weight of the tumors were measured. 
 
Western blot 
Tumors were homogenized in Passive Lysis Buffer (Promega Corporation, Madison, WI) 
with 1% Protease Inhibitor Cocktail (Sigma-Aldrich, Inc., St. Louis, MO). The homogenates were 
centrifuged at 15,000 × g for 10 min, and the supernatants were retained. The protein content was 
determined using the BCA protein assay kit. The supernatants were separated by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis, and proteins were transferred to Immobilon 
PVDF membranes (Millipore Corporation, Billerica, MA). After blocking with Blocking One 
(Nacalai Tesque, Inc., Kyoto, Japan) for 30 min, the membranes were probed with HER2 antibody 
(#2242, Cell Signaling Technology, Inc., Danvers, MA) at 4°C for 12 h. After washing 3 times with 
PBS containing 0.05% Tween20, anti-rabbit, horseradish peroxidase-linked antibody (#7074, Cell 
Signaling Technology, Inc.) was allowed to react with the proteins at room temperature for 45 min. 
All the antibodies were diluted 1:1000 with Can Get Signal (TOYOBO Co., Ltd., Osaka, Japan). 
After the washing step, the protein bands were visualized using Chemi-Lumi One Super (Nacalai 
Tesque, Inc.) with a gel imaging system (ChemiDoc XRS; BIO-RAD Laboratories, Hercules, CA).  
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Immunoblotting with β-actin was used as a protein-loading control. 
 
Statistical Analyses 
Comparisons between the 2 groups were made using the Student’s t-test. The analyses of 
the data from the therapeutic study were performed using 2-way analysis of variance (ANOVA) 
with repeated measures followed by a Tukey–Kramer multiple comparison test. A P value of <0.05 




Preparation of 67/68Ga-Df-anti-HER2 scFv 
The molecular weight of anti-HER2 scFv, Df-anti-HER2 scFv, and Ga-Df-anti-HER2 scFv 
was 27609.2, 27711.5, and 27771.2, respectively. This result indicates that 0.14 Df was introduced 
into the scFv on the average, and is in accordance with a previous report (0.2 Df per nanobody 
molecule) [16]. 
The radiochemical yield of 67Ga-Df-anti-HER2 scFv and 68Ga-Df-anti-HER2 scFv was 
83% and 86%, respectively. The radiochemical purity of both the probes was greater than 98%; its 
adsorption in PD-10 column was insignificant. 67Ga-Df-anti-HER2 scFv was obtained in a single 




The binding affinity of 67Ga-Df-anti-HER2 scFv was 9.94 ± 1.36 nM. This value represents 
the mean ± standard deviation of 3 examinations and is within the optimal range (1–100 nM) at 
which significant tumor uptake is expected [24]. 
 
In vitro stability 
The temporal changes in intact 67Ga-Df-anti-HER2 scFv in apo-transferrin solution are 
shown in Table 1. The radiochemical purity of 67Ga-Df-anti-HER2 scFv was maintained at levels 
greater than 95% after 3-h incubation with transferrin-containing NaHCO3 solution. No 
radioactivity was eluted in the transferrin fractions. The recovery of radioactivity from the HPLC 
column was 92.6 ± 6.4%. After 24-h incubation, the purity decreased to 48.1% and the recovery of 
radioactivity from the HPLC column was 77.5 ± 7.4%, suggesting that low-molecular weight 
byproducts were generated during 24-h incubation. 
In mouse plasma, 67Ga-Df-anti-HER2 scFv was also stable. All radioactivity was eluted in 
the fraction of monomeric 67Ga-Df-anti-HER2 scFv after 1-h incubation in mouse plasma. The 





The results of biodistribution study are presented in Table 2. The highest radioactivity was 
observed to accumulate in the kidneys. The radioactivity in blood at 1 h was higher than that in the 
tumors, but it decreased in a time-dependent manner. The radioactivity in N87 tumor increased in a 
time-dependent manner and was the highest among that in all the organs examined at 3 h, except for 
the kidneys. Significantly high radioactivity accumulated in N87 xenograft compared to that in 
Suit-2 xenograft at 2 and 3 h post injection. At 3 h post injection, the ratios of N87-to-blood, 
N87-to-Suit-2, and N87-to-muscle were 1.06 ± 0.17, 1.97 ± 0.24, and 7.92 ± 5.57, respectively. 
 
Autoradiography and Immunohistochemistry 
 Figure 1 shows the autoradiograms and the images of immunostained sections. 
Immunostaining revealed high expression of HER2 in the N87xenograft but no expression in the 
Suit-2 xenograft. The radioactivity accumulated regions in N87 xenograft coincided with the 
HER2-positive regions. On the other hand, the radioactivity accumulation in Suit-2 xenograft was 
low and homogenous. 
 
PET imaging 
Decay-uncorrected, serial PET images are shown in Fig. 2. N87 xenografts could be 
visualized in all the images, although radioactivity in the heart and liver was also high at 1 h post 
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injection, reflecting high radioactivity in blood. On the other hand, the radioactivity in Suit-2 
xenografts was at background level at all the time points. The radioactivity in N87 and Suit-2 
xenografts measured after dissection was 3.45%ID/g and 1.50%ID/g, respectively. The ratio of 
N87-to-Suit-2 was 2.30. 
 
Therapeutic study 
The effects of 17-DMAG on tumor growth and body weight are shown in Fig. 3. 
17-DMAG is an inhibitor of heat shock protein 90 (Hsp90) and is effective in many cancers [25]. 
After treatment with 17-DMAG, the size of N87 xenograft initially decreased but increased again 
from Day 5 onwards. The growth of Suit-2 xenograft was delayed for 11 days. In contrast, both the 
xenografts in the vehicle-treated group continued to grow and increased in size by a factor of 2.5–4 
by Day 14 (Fig. 3a). Two-way ANOVA demonstrated significant effects of the treatment (F3, 48 = 
48.9; P < 0.0001) and time (F5, 48 = 39.3; P < 0.0001) and a significant interaction between 
treatment and time (F15, 48 = 7.68; P < 0.0001) was observed. The size of N87 and Suit-2 xenografts 
in 17-DMAG-treated mice was significantly smaller than that of the vehicle-treated mice (P < 0.01). 
The body weight was similar between the vehicle and 17-DMAG-treated groups at any time point 
(Fig. 3b). 
 
Evaluation of HER2 expression by PET imaging and western blot analysis 
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Figure 4 shows the images of PET and western blotting in the identical xenograft after 
treatment with 17-DMAG. We chose to perform PET images at 2 h post injection because the 
effects of high background radioactivity and radioactive decay were more pronounced at 1 and 3 h 
post injection, respectively. The N87 xenograft could be clearly observed in the control mouse, 
while the Suit-2 xenograft was not visible. On the day after 17-DMAG treatment was concluded 
(Day 3), the tumor shrank and radioactivity accumulation, determined by the dissection method and 
PET imaging was 33% and 31%, respectively, as compared to that in control mice. Eleven days 
later (Day 14), radioactivity accumulation, determined by the dissection method and PET imaging 
was 66% and 75%, respectively, compared to that in control mice (Fig. 4a). These changes were in 
accordance with the changes in the expression of HER2 detected by western blotting. The signal 
density of HER2 normalized by β-actin was 29% and 76% compared to that of the control mice on 





Although trastuzumab and its fragmented derivatives have been labeled by various 
radionuclides [9, 10, 12, 13], the pharmacokinetics of these probes was too slow to be labeled by 
short half-lived radionuclide, 68Ga. To our knowledge, there is only 1 report regarding 
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68Ga-DOTA-conjugated antibody derivatives targeting HER2 [11]. The authors developed 
68Ga-DOTA-F(ab′)2-Herceptin and succeeded in performing the PET imaging of HER2-expressing 
tumor in mice. However, the condition of radiolabeling was unclear. Neither temperature, reaction 
time, nor radiochemical yield were mentioned in the manuscript. In fact, the radiochemical yield of 
68Ga-DOTA-anti HER2 scFv was less than 5% after 1-h incubation at room temperature in our 
preliminary experiment. On the other hand, rapid (<5min) radiolabeling by 67/68Ga was 
accomplished at room temperature with a high radiochemical yield (approximately 85%) by using 
deferoxamine as a bifunctional chelating agent. Since the molecular size of scFv was smaller than 
that of F(ab′)2, 68Ga-Df-anti-HER2 scFv showed faster blood clearance (scFv: 5.44%ID/g at 3 h, 
F(ab′)2: > 15%ID/g at 3.5 h) and better tumor-to-blood ratio (scFv: 1.06 at 3 h, F(ab′)2: < 1 at 3.5 h) 
than 68Ga-DOTA-F(ab′)2-Herceptin did [11]. 
Recently, several protein-engineered, antibody-mimetic probes, called “affibody molecules” 
have been developed and labeled with 68Ga to target and image HER2. Among them, 1 of the most 
promising probes is 68Ga-ABY-002, which was used in humans for the first time and was 
successfully employed for imaging HER2-expressing tumors in breast cancer patients [26]. In 
preclinical experiment, 68Ga-ABY-002 showed approximately 2-fold higher accumulation 
(12.4%ID/g at 2 h) in HER2-positive xenografts compared to 68Ga-Df-anti-HER2 scFv (5.21%ID/g 
at 2 h), although the xenografts were made by using different cell lines [27]. The accumulation of 
68Ga-DOTA-MUT-DS (4.12%ID/g at 2 h) and 68Ga-ZHER2:342min (2.40%ID/g at 2 h) in 
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HER2-positive xenografts was comparable to that of 68Ga-Df-anti-HER2 scFv at the same time 
point [28, 29]. However, both affibody probes showed better tumor-to-blood ratio than 
68Ga-Df-anti-HER2 scFv. Therefore, structural modification of 68Ga-Df-anti-HER2 scFv is required 
to improve the blood ratio. 
Although 68Ga-Df-anti-HER2 scFv showed faster blood clearance than radiolabeled 
trastuzumab and its fragmented derivative, the radioactivity of 68Ga-Df-anti-HER2 scFv in blood 
was higher than those of the other scFv probes [30, 31]. Gallium is reported to form a complex with 
transferrin, which exists in blood [32]. However, from transferrin challenge studies in the presence 
of carbonate, we found that 67Ga-Df-anti-HER2 scFv was stable in the presence of apo-transferrin, 
without the occurrence of transchelation reaction with transferrin. Furthermore, 67Ga-Df-anti-HER2 
scFv existed as an intact monomer in mouse plasma and showed no interaction with serum proteins. 
These results correlate with high stability of the 67/68Ga-nanobody probe previously reported in 
human serum, using the same bifunctional chelating agent as in the present study [16]. Thus, slow 
blood clearance is not attributable to a transchelation reaction with transferrin followed by 
circulation of 68Ga-transferrin in blood, interaction with serum proteins, or dimerization. The reason 
for slow blood clearance of 67Ga-Df-anti-HER2 scFv still remains unclear. Some radioactivity 
existed in blood cell fractions, suggesting interaction between 67Ga-Df-anti-HER2 scFv and blood 
cells, and may be a possible reason for delayed blood clearance of 67Ga-Df-anti-HER2 scFv. 
Trastuzumab (Herceptin) has been approved for the treatment of HER2-positive breast 
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cancer and metastatic gastric cancer [33, 34]. Thus, the radioactivity ratios of tumor-to-thoracic and 
abdominal organs are important to evaluate HER2 expression by using 68Ga-Df-anti-HER2 scFv. 
The biodistribution study indicated that the highest radioactivity accumulated in the kidneys. 
Although tumor-to-stomach ratio was greater than 1, the high radioactivity in the kidneys may 
hamper the application of 68Ga-Df-anti-HER2 scFv for metastatic gastric cancer. However, it would 
interfere the least with the imaging quality of breast cancer, which is distant from the kidneys. Since 
the ratios of tumor-to-heart and lung were greater than 1 after 2 h post injection, 68Ga-Df-anti-HER2 
scFv is capable of monitoring the HER2 expression of breast cancer noninvasively. 
In PET study, the protein concentration of 68Ga-Df-anti-HER2 scFv was approximately 
50-fold higher than that of 67Ga-Df-anti-HER2 scFv used for the biodistribution study. Although the 
tumoral accumulation of 68Ga-Df-anti-HER2 scFv in PET study was lower than that in 
biodistribution study, the radioactivity ratio of HER2-positive-to-negative xenografts was 
comparable in both the studies. Thus, the difference in the specific activity of the probe probably 
did not affect the probe distribution. Specific activity of 68Ga-Df-anti-HER2 scFv used for PET 
study (0.2–0.4 MBq/μg) was comparable to that of other 68Ga-labeled probes (0.4–0.6 MBq/μg) that 
were successful in PET imaging of HER2-positive xenografts [27, 28]. Reduction of blood flow 
under anesthesia may cause low accumulation of 68Ga-Df-anti-HER2 scFv in PET study.  
Hsp90 is a molecular chaperone that plays an important role in the maturation and stability 
of client proteins. Since HER2 is one of the most sensitive target proteins of Hsp90, it is expected 
23 
that the Hsp90 inhibitors would be effective against HER2-overexpressing tumors [35]. Therefore, 
we used 17-DMAG for anti-HER2 therapy, which is the first Hsp90 inhibitor approved for clinical 
trials [36], and succeeded in monitoring HER2 status after therapy by noninvasive PET imaging. 
Chandarlapaty et al. reported that combined therapy of trastuzumab and a Hsp90 inhibitor was 
effective for treating trastuzumab-resistant breast cancer [37] and phase I dose-escalation clinical 
trial of trastuzumab and 17-DMAG were recently performed [38]. Since the anti-HER2 scFv used 
in this study recognizes the same epitope as trastuzumab, the monitoring of HER2 status during the 
combination therapy is unfortunately difficult. Affibody-based probes can overcome this issue 
because they bind to distinct epitopes on the HER2 extracellular domain, which is different from the 




By using deferoxamine as a bifunctional chelate, 68Ga-labeled scFv targeting HER2 was 
rapidly obtained under mild labeling conditions. 68Ga-Df-anti-HER2 scFv maintained its 
immunoreactivity and showed high accumulation in HER2-positive xenografts. The intratumoral 
distribution of radioactivity coincided with HER2-positive regions. Although low tumor-to-blood 
ratio needs to be improved, 68Ga-Df-anti-HER2 scFv successfully visualized HER2-positive 
xenografts and monitored the changes in HER2 expression after therapy. Thus, 68Ga-Df-anti-HER2 
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scFv could be a promising probe to evaluate HER2 status by in vivo PET imaging, unless 
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Table 1. In vitro stability of 67Ga-Df-anti-HER2 scFv 
Incubation time (h) Intact form (%) 
1 97.1 ± 1.3 
2 95.5 ± 0.2 
3 95.4 ± 0.3 
24 48.1 ± 2.6 




Table 2. Biodistribution of 67Ga-Df-anti-HER2 scFv in tumor-bearing mice 
 Time after injection (h) 
Organ 1 2 3 
Blood 10.87 ± 1.07 7.00 ± 1.26 5.44 ± 1.36 
N87 xenograft 4.57 ± 1.78 5.21 ± 1.31* 5.58 ± 0.86** 
Suit-2 xenograft 3.25 ± 0.88 3.24 ± 0.68 2.90 ± 0.76 
Muscle 1.84 ± 0.81 1.22 ± 0.31 1.01 ± 0.67 
Heart 3.82 ± 0.70 2.87 ± 0.46 2.22 ± 0.64 
Lung 6.09 ± 1.22 3.89 ± 0.92 3.51 ± 0.57 
Stomach 2.17 ± 1.19 2.61 ± 0.92 1.89 ± 0.95 
Spleen 3.06 ± 0.62 2.50 ± 0.75 2.65 ± 0.80 
Pancreas 1.75 ± 0.54 1.61 ± 0.55 1.77 ± 0.69 
Liver 6.33 ± 1.62 5.71 ± 0.77 4.86 ± 0.30 
Kidneys 124.08 ± 28.04 129.68 ± 14.78 106.84 ± 18.38 
Intestine 3.26 ± 0.40 3.91 ± 0.49 5.15 ± 0.44 
Organ uptake values are expressed as percent injected dose per gram of tissue.  
Values are represented as mean ± S.D., n = 4–5. 







Representative images of autoradiograms and HER2 immunostainings in N87 (a, c) and Suit-2 (b, 
d) xenografts. Strong HER2 expression was observed only in N87 xenograft (c). The radioactivity 








Representative PET images of N87- and Suit-2-implanted mice with 68Ga-Df-anti-HER2 scFv. 
Images are shown at the same scale and not corrected by radioactive decay. Arrowheads and arrows 








(a) Changes in the growth of N87 and Suit-2 xenografts of mice treated with vehicle or 17-DMAG. 
Vehicle or 17-DMAG was injected once a day for 3 consecutive days, as indicated by the arrows. 
Each data point represents an average of 3 mice, and each error bar represents the standard 
deviation. Open symbols represent data obtained from vehicle-treated mice and closed symbols 
represent those obtained from 17-DMAG-treated mice (* indicates P < 0.05; ** indicates P < 0.01). 
(b) Changes in body weight of mice treated with vehicle or 17-DMAG. Vehicle or 17-DMAG was 
injected once a day for 3 consecutive days, as indicated by arrows. Each data point represents an 
average of 3 mice and each error bar represents the standard deviation. There was no significant 






(a) Effect of 17-DMAG treatment assessed by PET images of N87- and Suit-2-implanted mice 
acquired at 2 h post injection of 68Ga-Df-anti-HER2 scFv. Arrowheads and arrows indicate N87 and 
Suit-2 xenografts, respectively. 
(b) Western blot analysis of HER2 expression in N87 xenografts. The samples derived from control 
mice (C) and 17-DMAG-treated mice (3 and 14) were analyzed. The numbers indicate the number 
of days from the initial administration of 17-DMAG. The bands of β-actin are shown as a 
protein-loading control. M, molecular size marker. 
 
